Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
在显性遗传性阿尔茨海默病中，评估甘特鲁单抗或索拉内珠单抗在试验中期剂量递增后，生物标志物、临床和认知结果的剂量依赖性治疗效果
期刊:Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
影响因子:4.4
doi:10.1002/dad2.12367
Wang, Guoqiao; Li, Yan; Xiong, Chengjie; McDade, Eric; Clifford, David B; Mills, Susan L; Santacruz, Anna M; Aschenbrenner, Andrew J; Hassenstab, Jason; Benzinger, Tammie L S; Gordon, Brian A; Fagan, Anne M; Coalier, Kelley A; Libre-Guerra, Jorge J; McCullough, Austin; Joseph-Mathurin, Nelly; Chen, Charles D; Mummery, Catherine; Wendelberger, Barbara A; Gauthier, Serge; Masellis, Mario; Holdridge, Karen C; Yaari, Roy; Chatterjee, Saptarshi; Sims, John; Delmar, Paul; Kerchner, Geoffrey A; Bittner, Tobias; Hofmann, Carsten; Bateman, Randall J
